Dr. Sulaiman Al Habib Medical Services Group Valuation

Is 4013 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4013 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4013 (SAR298.6) is trading below our estimate of fair value (SAR375.61)

Significantly Below Fair Value: 4013 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4013?

Key metric: As 4013 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4013. This is calculated by dividing 4013's market cap by their current earnings.
What is 4013's PE Ratio?
PE Ratio	46.9x
Earnings	ر.س2.23b
Market Cap	ر.س104.51b

4013 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.4x
Enterprise Value/EBITDA	42.5x
PEG Ratio	3.1x

Price to Earnings Ratio vs Peers

How does 4013's PE Ratio compare to its peers?

The above table shows the PE ratio for 4013 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	34.9x
4002 Mouwasat Medical Services	26.6x	16.4%	ر.س17.5b
4017 Dr. Soliman Abdel Kader Fakeeh Hospital	54.7x	19.1%	ر.س15.7b
4004 Dallah Healthcare	31.5x	14.9%	ر.س14.8b
4005 National Medical Care	26.9x	11.2%	ر.س7.4b
4013 Dr. Sulaiman Al Habib Medical Services Group	46.9x	15.1%	ر.س104.5b

Price-To-Earnings vs Peers: 4013 is expensive based on its Price-To-Earnings Ratio (46.9x) compared to the peer average (34.9x).

Price to Earnings Ratio vs Industry

How does 4013's PE Ratio compare vs other companies in the Asian Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 4013 is expensive based on its Price-To-Earnings Ratio (46.9x) compared to the Asian Healthcare industry average (20.9x).

Price to Earnings Ratio vs Fair Ratio

What is 4013's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4013 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	46.9x
Fair PE Ratio	38.3x

Price-To-Earnings vs Fair Ratio: 4013 is expensive based on its Price-To-Earnings Ratio (46.9x) compared to the estimated Fair Price-To-Earnings Ratio (38.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4013 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	ر.س298.60	ر.س305.83 +2.4%	9.9%	ر.س360.00	ر.س245.00	n/a	12
Dec ’25	ر.س273.00	ر.س300.45 +10.1%	8.8%	ر.س347.00	ر.س245.00	n/a	11
Nov ’25	ر.س286.20	ر.س301.90 +5.5%	9.5%	ر.س347.00	ر.س245.00	n/a	10
Oct ’25	ر.س295.40	ر.س302.67 +2.5%	9.9%	ر.س347.00	ر.س245.00	n/a	9
Sep ’25	ر.س303.40	ر.س301.56 -0.6%	10.1%	ر.س347.00	ر.س245.00	n/a	9
Aug ’25	ر.س284.00	ر.س292.44 +3.0%	7.8%	ر.س323.00	ر.س245.00	n/a	9
Jul ’25	ر.س283.00	ر.س295.60 +4.5%	8.5%	ر.س330.00	ر.س245.00	n/a	10
Jun ’25	ر.س268.20	ر.س287.10 +7.0%	13.2%	ر.س330.00	ر.س200.00	n/a	10
May ’25	ر.س311.00	ر.س290.31 -6.7%	14.1%	ر.س345.00	ر.س200.00	n/a	10
Apr ’25	ر.س309.00	ر.س284.31 -8.0%	15.9%	ر.س345.00	ر.س200.00	n/a	10
Mar ’25	ر.س329.40	ر.س280.01 -15.0%	15.5%	ر.س345.00	ر.س200.00	n/a	10
Feb ’25	ر.س292.80	ر.س275.91 -5.8%	15.9%	ر.س345.00	ر.س200.00	n/a	10
Jan ’25	ر.س288.20	ر.س262.70 -8.8%	13.5%	ر.س330.00	ر.س200.00	n/a	10
Dec ’24	ر.س282.00	ر.س256.00 -9.2%	12.6%	ر.س300.00	ر.س200.00	ر.س273.00	10
Nov ’24	ر.س257.00	ر.س249.44 -2.9%	12.4%	ر.س300.00	ر.س200.00	ر.س286.20	9
Oct ’24	ر.س240.40	ر.س246.22 +2.4%	12.9%	ر.س300.00	ر.س200.00	ر.س295.40	9
Sep ’24	ر.س243.00	ر.س255.13 +5.0%	12.5%	ر.س300.00	ر.س210.00	ر.س303.40	8
Aug ’24	ر.س284.60	ر.س258.56 -9.2%	11.7%	ر.س300.00	ر.س210.00	ر.س284.00	9
Jul ’24	n/a	ر.س258.56 0%	11.7%	ر.س300.00	ر.س210.00	ر.س283.00	9
Jun ’24	ر.س262.00	ر.س252.57 -3.6%	11.1%	ر.س295.00	ر.س210.00	ر.س268.20	7
May ’24	ر.س293.80	ر.س243.25 -17.2%	14.3%	ر.س295.00	ر.س193.00	ر.س311.00	8
Apr ’24	ر.س291.40	ر.س233.88 -19.7%	16.0%	ر.س270.00	ر.س180.00	ر.س309.00	8
Mar ’24	ر.س237.00	ر.س231.14 -2.5%	17.0%	ر.س270.00	ر.س180.00	ر.س329.40	7
Feb ’24	ر.س240.20	ر.س216.73 -9.8%	18.3%	ر.س270.00	ر.س174.10	ر.س292.80	7
Jan ’24	ر.س222.80	ر.س216.73 -2.7%	18.3%	ر.س270.00	ر.س174.10	ر.س288.20	7
Dec ’23	ر.س234.00	ر.س216.73 -7.4%	18.3%	ر.س270.00	ر.س174.10	ر.س282.00	7

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 05:49
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dr. Sulaiman Al Habib Medical Services Group Company is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jassim Al-Jubran	Aljazira Capital Company
Madhu Appissa	Al Rajhi Capital
Christine Kalindjian	Arqaam Capital Research Offshore S.A.L.